Literature DB >> 9443912

Engineered mutants of HGF/SF with reduced binding to heparan sulphate proteoglycans, decreased clearance and enhanced activity in vivo.

G Hartmann1, T Prospero, V Brinkmann, C Ozcelik, G Winter, J Hepple, S Batley, F Bladt, M Sachs, C Birchmeier, W Birchmeier, E Gherardi, O Ozcelik.   

Abstract

BACKGROUND: Although a number of growth factors bind cell-surface heparan sulphate proteoglycans (HSPGs), the role of this interaction is unclear except for fibroblast growth factor which requires HSPG binding for signalling. Hepatocyte growth factor/scatter factor (HGF/SF) plays important roles in mammalian development and tissue regeneration and acts on target cells through a specific receptor tyrosine kinase encoded by the c-met proto-oncogene. This factor also binds HSPGs with high affinity, but conflicting data have been reported on the role of HSPG binding in HGF/SF signalling.
RESULTS: To map the binding sites for HSPG and the Met receptor in HGF/SF, we have engineered a number of HGF/SF mutants in which several clusters of solvent-accessible residues in the hairpin structure of the amino-terminal domain or in kringle 2 have been replaced. Two of the mutants (HP1 and HP2) showed greatly decreased (more than 50-fold) affinity for heparin and HSPGs but retained full mitogenic and motogenic activities on target cells in culture. Furthermore, when compared with wild-type HGF/SF, the HP1 mutant exhibited a delayed clearance from the blood, higher tissue levels and a higher induction of DNA synthesis in normal, adult murine liver.
CONCLUSIONS: These results establish the following: the binding sites in HGF/SF for Met and for HSPGs can be dissociated by protein engineering; high-affinity binding of HGF/SF to HSPGs is not essential for signalling; one role of HSPG binding in the HGF/SF system appears to be sequestration and degradation of the growth factor; and HGF/SF mutants with decreased affinity for HSPGs exhibit enhanced activity in vivo.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9443912     DOI: 10.1016/s0960-9822(98)70059-4

Source DB:  PubMed          Journal:  Curr Biol        ISSN: 0960-9822            Impact factor:   10.834


  27 in total

1.  Large-plaque mutants of Sindbis virus show reduced binding to heparan sulfate, heightened viremia, and slower clearance from the circulation.

Authors:  A P Byrnes; D E Griffin
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  CD44 is required for two consecutive steps in HGF/c-Met signaling.

Authors:  Véronique Orian-Rousseau; Linfeng Chen; Jonathan P Sleeman; Peter Herrlich; Helmut Ponta
Journal:  Genes Dev       Date:  2002-12-01       Impact factor: 11.361

3.  An allosteric switch for pro-HGF/Met signaling using zymogen activator peptides.

Authors:  Kyle E Landgraf; Micah Steffek; Clifford Quan; Jeffrey Tom; Christine Yu; Lydia Santell; Henry R Maun; Charles Eigenbrot; Robert A Lazarus
Journal:  Nat Chem Biol       Date:  2014-05-25       Impact factor: 15.040

4.  An engineered dimeric fragment of hepatocyte growth factor is a potent c-MET agonist.

Authors:  Cassie J Liu; Douglas S Jones; Ping-Chuan Tsai; Abhishek Venkataramana; Jennifer R Cochran
Journal:  FEBS Lett       Date:  2014-11-21       Impact factor: 4.124

5.  CAR T-cell immunotherapy of MET-expressing malignant mesothelioma.

Authors:  Thivyan Thayaparan; Roseanna M Petrovic; Daniela Y Achkova; Tomasz Zabinski; David M Davies; Astero Klampatsa; Ana C Parente-Pereira; Lynsey M Whilding; Sjoukje Jc van der Stegen; Natalie Woodman; Michael Sheaff; Jennifer R Cochran; James F Spicer; John Maher
Journal:  Oncoimmunology       Date:  2017-08-14       Impact factor: 8.110

6.  Crystal structures of NK1-heparin complexes reveal the basis for NK1 activity and enable engineering of potent agonists of the MET receptor.

Authors:  D Lietha; D Y Chirgadze; B Mulloy; T L Blundell; E Gherardi
Journal:  EMBO J       Date:  2001-10-15       Impact factor: 11.598

7.  Heparin-mediated selective release of hepatocyte growth factor in humans.

Authors:  P B Salbach; M Brückmann; O Turovets; J Kreuzer; W Kübler; I Walter-Sack
Journal:  Br J Clin Pharmacol       Date:  2000-09       Impact factor: 4.335

Review 8.  Syndecan-4: dispensable or indispensable?

Authors:  Sarah A Wilcox-Adelman; Fabienne Denhez; Tokuro Iwabuchi; Stefania Saoncella; Enzo Calautti; Paul F Goetinck
Journal:  Glycoconj J       Date:  2002 May-Jun       Impact factor: 2.916

Review 9.  CD44 in cancer progression: adhesion, migration and growth regulation.

Authors:  R Marhaba; M Zöller
Journal:  J Mol Histol       Date:  2004-03       Impact factor: 2.611

10.  Met provides essential signals for liver regeneration.

Authors:  Malgorzata Borowiak; Alistair N Garratt; Torsten Wüstefeld; Michael Strehle; Christian Trautwein; Carmen Birchmeier
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.